GlassScriptPhysician profile
Ranine Ghamrawi
NPI 1821473109
$15,512.53
in general payments reported to CMS, 2019-2025
22 companies · $10K in 2025
The $10K reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2021: $131 · 2022: $495 · 2023: $3,113 · 2024: $1,412 · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $3,517 · Travel and Lodging: $376 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $274 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,612.46 |
| Food and Beverage | $3,516.56 |
| Travel and Lodging | $376.30 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $274.00 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $8,155.67 | 2022-2025 | Voyxact |
| Calliditas Therapeutics US INC. | $4,176.53 | 2024-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $752.80 | 2022-2025 | Jynarque, Voyxact |
| Fresenius USA Marketing, INC. | $440.11 | 2021-2025 | Velphoro, Velphoro |
| Astrazeneca Pharmaceuticals LP | $210.12 | 2022-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $195.38 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $189.58 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $186.76 | 2024-2025 | |
| Amgen INC. | $179.84 | 2023-2025 | Tavneos |
| Vifor Pharma, INC. | $166.98 | 2021-2023 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $136.75 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $124.99 | 2025 | Wegovy |
| Galderma Laboratories, L.P. | $104.18 | 2019 | |
| Ardelyx, INC. | $91.83 | 2024-2025 | Ibsrela |
| Medtronic, INC. | $84.79 | 2024 | Ellipsys Vascular Access System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $76.82 | 2024 | Crysvita |
| Alexion Pharmaceuticals, INC. | $72.53 | 2024 | Ultomiris |
| Mallinckrodt Hospital Products INC. | $70.78 | 2023-2024 | Acthar |
| Daiichi Sankyo INC. | $30.15 | 2022-2023 | Injectafer |
| Genzyme Corporation | $28.56 | 2023 | |
| Akebia Therapeutics INC | $21.62 | 2023 | Auryxia |
| Amag Pharmaceuticals, INC. | $15.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ranine Ghamrawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.